Company: LIMN
Filing Date: 2025-04-30
Form Type: 8-K12B
Source: 0001104659-25-042489
Chunk: 1

Company: Liminatus Pharma, Inc.
Filing Date: 2025-04-30
Form: 8-K12B
Chunk 1
---
 the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company x

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨

<div align='center'>EXPLANATORY NOTE</div>

On April 30, 2025, Iris Acquisition Corp, a Delaware
corporation (formerly known as Tribe Capital Growth Corp I) (“IRAA”), Liminatus Pharma, Inc., a Delaware corporation (formerly
known as Iris Parent Holding Corp.) (“LIMN”), Liminatus Pharma, LLC, a Delaware limited liability company (“Liminatus”),
Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LIMN (“Liminatus Merger Sub”), and
SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of LIMN (“SPAC Merger Sub”), completed a business
combination transaction pursuant to that certain Business Combination Agreement, dated as of November 30, 2022 (as it may be amended,
supplemented or otherwise modified from time to time, the “Business Combination Agreement”).

Upon the terms and subject to the conditions set
forth in the Business Combination Agreement and in accordance with the Delaware Limited Liability Company Act and the Delaware General
Corporation Law, (a) Liminatus Merger Sub merged with and into Liminatus (the “Liminatus Merger”), with Liminatus surviving
the Liminatus Merger as a direct wholly-owned subsidiary of LIMN, and (b) simultaneously with the Liminatus Merger, SPAC Merger Sub merged
with and into IRAA (the “SPAC Merger”), with IRAA surviving the SPAC Merger as a direct wholly-owned subsidiary of LIMN.

As a result of the SPAC Merger, (i) shares of
IRAA common stock were converted into shares of LIMN common stock, and (ii) IRAA’s warrants to purchase shares of IRAA common stock
were converted into LIMN’s warrants to purchase shares of LIMN common stock. Upon the closing of the business combination transaction,
the combined company was named “Liminatus Pharma, Inc.” and its securities are listed on The Nasdaq Stock Market.

Accordingly, L